Roundup Settlement Final Approval Rests With Judge Boyer After a $7.25 Billion Fairness Hearing

Roundup settlement final approval now turns on a single St. Louis judge

Judge Timothy Boyer of the Circuit Court of the City of St. Louis heard final argument on Monday 14 September 2026 on whether to approve Monsanto's $7.25 billion nationwide Roundup class settlement, gave no signal that he would rule from the bench, and directed the parties to file proposed orders by the end of that week. As of 18 September 2026, Roundup settlement final approval has not issued: the record is closed, the drafts are in, and a deal that would bind roughly 65,000 pending non-Hodgkin lymphoma claims and an open-ended nationwide futures subclass sits entirely with one state trial judge.

That is the whole of the news, and it is more consequential than its procedural flatness suggests. The case, King v. Monsanto Co., is being litigated in Missouri's 22nd Judicial Circuit rather than in the federal Multidistrict Litigation (MDL) where Roundup spent most of the last decade, and it asks a state court to do something no American court has done at this scale for a live consumer product: certify a Settlement Class that sweeps in people who have not been injured yet, release their Punitive Damages claims, hold their compensatory claims inside a matrix for sixteen years, and leave the product on the shelves throughout.

Has the Roundup settlement been approved?

No. Preliminary approval was granted on 4 March 2026; final approval has not been granted, denied, or conditioned, and the court has not published a timetable for deciding. Reporting from the hearing is consistent that Boyer gave no indication of ruling immediately, and The New Lede reported that he told the courtroom he could not predict how long the decision would take.

Until an order issues, three things follow. The Class Notice program's legal effect remains provisional — nobody's claim has been released. The 4 June 2026 opt-out deadline has passed, so the population that will be bound is already fixed subject to the validity disputes discussed below. And every claimant who stayed in is in a holding pattern: eligible to file with the Claims Administrator under the program's terms if and when the order lands, and otherwise holding an unreleased tort claim that the Supreme Court materially devalued in June.

What happened at the Roundup settlement fairness hearing on 14 September 2026?

Boyer convened what has been described in the trade press as a lengthy fairness hearing precisely because his preliminary approval had been attacked by a bloc of plaintiffs' lawyers who represent class members and want no part of the deal. The hearing was therefore adversarial in a way that final approval hearings often are not. Monsanto's counsel and class counsel defended the structure; an organized group of Objector counsel attacked it; and — a detail The New Lede and ALM's trade coverage both picked up — several lawyers who had originally opposed the settlement appeared to speak in its favor, a shift that class counsel will cite as evidence that the bar's objections have narrowed rather than hardened.

The objectors' central line was that the arrangement is collusive: that it buys global peace for Monsanto and a $675 million fee for the firms that built it, while paying class members amounts they characterize as inadequate for a fatal cancer. One objecting attorney, quoted in coverage of the hearing, framed the futures problem in terms that will follow this settlement into any appeal: it is, on that account, the first future settlement "to ever lock in people … with no punitive damage to a 20-year claims period, and keep the product that they were exposed to on the market, allowing the victims to continue to be exposed to that product." Another strand of the argument, reported under the headline that the settlement "is the scariest," went to the court's power to bind residents of other states through a Missouri class judgment.

Monsanto's position, stated by a company spokesman, is that the settlement "is supported by plaintiffs' counsel representing tens of thousands of potential class members, is fair to all parties and warrants final approval." Bayer has been explicit that it regards the class device, rather than another round of individual settlements, as the only structure capable of ending the litigation's long tail.

How much will claimants get from the $7.25 billion Roundup settlement?

Individual awards run from roughly $10,000 to $165,000, assigned across nine tiers keyed to exposure setting, age at diagnosis, and the aggressiveness of the disease. Occupational exposure — agricultural, landscaping and grounds-keeping use — reaches the top of the range; residential use is capped materially lower. A separate quick-pay option pays a flat, smaller sum to claimants who had already filed suit or entered a Tolling Agreement before the settlement was struck.

The Settlement Matrix is not the only number that matters. Monsanto does not fund $7.25 billion on day one. It makes declining capped annual payments across a 17-to-21-year schedule, secured by a $1 billion fund intended to protect claimants against default or bankruptcy. That structure is a meaningful part of the objectors' case, because the nominal headline figure and the present value of the promise are two different things, and because the annual caps determine how quickly claims can actually be paid in the years when filings are heaviest.

Term	What the settlement provides
Headline value	Up to $7.25 billion
Funding schedule	Declining capped annual payments over 17 to 21 years
Security	$1 billion fund against default or insolvency
Individual award range	Approximately $10,000 to $165,000
Tiering	Nine tiers by exposure setting, age at diagnosis and disease severity
Occupational exposure	Top of the range, up to approximately $165,000
Residential exposure	Capped substantially lower, up to approximately $40,000
Quick-pay option	Approximately $6,000 to $14,500, limited to claimants who filed suit or a tolling agreement before 13 February 2026
Futures window	Claims may be submitted on diagnosis for sixteen years after final approval
Release	Compensatory, punitive and medical-monitoring claims against Monsanto, Bayer and related entities
Class counsel fee request	$675 million, payable from within the fund
Preliminary approval	4 March 2026
Opt-out and objection deadline	4 June 2026
Final approval hearing	14 September 2026, decision reserved

Who is covered by the Roundup class settlement?

Two subclasses. The first is composed of current claimants: people already diagnosed with non-Hodgkin lymphoma as of the settlement date, whether or not they had filed suit. The second is the futures subclass, and it is the reason this deal is a landmark rather than a large ordinary Global Settlement — it captures everyone in the United States exposed to Roundup before 17 February 2026 who has not yet been diagnosed.

A futures class member cannot file a claim for payment. There is nothing to claim until a diagnosis arrives. What the settlement does to that person in the meantime is remove the option of suing on their own terms later, substituting a matrix payment available on diagnosis within a sixteen-year window. If no diagnosis has arrived by the sixteenth annual payment date, the settlement returns the person's legal rights intact. The bet embedded in the design is that latency will run out before the window does for most of the class; the objectors' bet is the opposite.

This is also where the Statute of Limitations intersects with class design in a way practitioners should watch. A futures class member's clock does not start until a diagnosis and, under the Discovery Rule as applied in most states, until the causal link is or should be known. The settlement effectively replaces that individualized timing analysis with a single administrative deadline running from the date of an order that has not yet issued.

What does a judge have to find before granting Roundup settlement final approval?

Missouri Rule of Civil Procedure 52.08 tracks Federal Rule of Civil Procedure 23 closely enough that the analysis will look familiar to any MDL practitioner, and it imposes two distinct burdens that the fairness hearing was convened to test. Boyer must first be satisfied that the class can be certified at all — Numerosity, Commonality, Typicality and Adequacy of Representation, plus, for a damages class, the Predominance of common questions over individual ones and the Superiority of the class device over the alternatives. He must then find separately that the settlement itself is fair, reasonable and adequate.

The two findings are not interchangeable, and the distinction is where this deal is most exposed. A settlement can be generous and still fail certification if the representation was structurally conflicted, which is the precise lesson of Amchem and Ortiz: the Supreme Court rejected both asbestos settlements not because the money was too little but because one set of class counsel could not adequately represent the presently injured and the exposure-only claimants simultaneously. Certification is also not softened by the fact that a settlement is on the table. Amchem held that a court reviewing a settlement class may put manageability aside, because there will be no trial — but every other requirement, adequacy above all, applies with undiminished force, and demands more scrutiny rather than less where the class was assembled for the purpose of settling.

Superiority carries unusual weight here too, and it has moved since certification. Superiority is measured against the realistic alternative, and after Durnell the realistic alternative for most class members is a preempted claim. Class counsel will press that point hard; objectors will answer that a court cannot bootstrap Adequacy of Representation out of a mid-stream change in the law that arrived after the class was notified and after the window to leave had closed.

Why are lawyers objecting to the $7.25 billion Roundup settlement?

More than 100 class members and roughly a dozen health care plans filed objections, and the grounds cluster into five categories.

Notice. Objectors argue that the Class Notice could not have reached a futures subclass that includes people who do not know they were exposed, do not know they are class members, and have no injury to prompt them to read a notice. A related filing in May 2026 put the point in constitutional terms, arguing that the design runs "roughshod over basic due process rights" and binds people — including, on the objectors' framing, those not yet born — to a bargain they had no realistic chance to evaluate.

Opt-out mechanics. The opt-out route has been described by objectors as onerous to the point of being illusory for undiagnosed class members, who had 90 days from preliminary approval to decide whether to preserve rights in a disease they do not have.

Jurisdiction. A Missouri circuit court is being asked to enter a judgment binding residents of every other state on claims arising everywhere. That is a familiar feature of nationwide class settlements, but it draws sharper scrutiny where the class is mandatory in practical effect and where the forum was selected by the settling parties.

Adequacy of Representation. This is the objection with the most precedent behind it. Amchem Products, Inc. v. Windsor and Ortiz v. Fibreboard Corp. both refused to let a single set of class counsel represent presently injured and future claimants without structural protection, because the two groups want different things from the same finite fund: the currently sick want money now, and the not-yet-sick want money preserved for later. Objectors say the Roundup structure reproduces exactly that conflict, and that separate subclass counsel and separate allocation do not cure it where a single negotiating team set both the fund and the caps.

The release. Class members give up compensatory, punitive and medical-monitoring claims. Stripping Punitive Damages from a product-liability population whose largest verdicts were overwhelmingly punitive is, to the objectors, the settlement's real concession — and one they say is not priced into a $165,000 ceiling.

How much are the lawyers getting paid, and how does $675 million compare?

Class counsel seek $675 million, which is approximately 9.3 percent of the $7.25 billion maximum and is payable from inside the fund rather than in addition to it. The negotiating firms are Holland Law Firm, Ketchmark & McCreight, Motley Rice, Seeger Weiss, Waters Kraus Paul & Siegel, and Williams Hart & Boundas.

Measured against ordinary Common Fund Doctrine practice, 9.3 percent is not an outlier on the high side — megafund settlements routinely draw percentage awards below the 25 percent benchmark precisely because the fee scales with a number that did not require proportionally more work to produce. Measured against what class members receive, it reads very differently, and that is the comparison objectors put in front of Boyer: a nine-figure fee certain, against matrix payments that for residential users top out around $40,000 and arrive over a two-decade schedule.

Two features complicate the arithmetic in ways no competitor coverage has set out. First, because the fund pays out over 17 to 21 years while fees are sought now, the fee's effective percentage of the settlement's present value is higher than 9.3 percent. Second, the futures subclass contributes nothing to the fund today and may contribute claims for sixteen years; a fee fixed against the headline maximum is therefore a fee partly earned on behalf of people who cannot yet be identified. Missouri practice permits a court to hold back or stage a fee award, and whether Boyer does so is one of the few dials he can turn without rejecting the deal outright.

How does Monsanto v. Durnell affect the Roundup settlement?

Decisively, and in Monsanto's favor. On 25 June 2026 the Supreme Court decided Monsanto Co. v. Durnell, No. 24-1068, by 7-2, with Justice Kavanaugh writing for the Court, Justice Thomas concurring, and Justices Gorsuch and Jackson dissenting. The holding is that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts a state-law Failure to Warn claim where the claim would require a cancer warning in addition to, or different from, the labeling the EPA has approved. The $1.25 million Missouri verdict for John Durnell was reversed.

Because Failure to Warn was the theory carrying the overwhelming majority of Roundup claims, Durnell converted the litigation's dominant cause of action into a Preemption (Products) problem almost overnight. The practical effect on the settlement was immediate and measurable: claimants who had opted out to preserve a trial option found that option sharply devalued, and the settlement administrator was flooded with requests to revoke opt-outs. Monsanto asked for roughly three additional weeks to process those revocations and to litigate which opt-outs were valid in the first place; the court granted the continuance on 6 August 2026, moving the hearing from 19 August to 14 September.

The doctrinal point for the fairness inquiry is uncomfortable for both sides. Class counsel can now argue that the settlement is a better deal than it looked in February, because the litigation alternative is worse. Objectors answer that a settlement's adequacy is measured against the claims as they existed when the class was certified and notice went out — and that Durnell arriving after the opt-out deadline is exactly why the notice and opt-out process should not be treated as having given class members an informed choice.

Can claimants still opt out of the Roundup settlement?

No. The opt-out and objection window ran for 90 days from preliminary approval and closed on 4 June 2026. What remains live is the mirror-image question: whether class members who did opt out can withdraw those exclusions and come back in after Durnell, and whether particular opt-outs were validly executed in the first place. Both sets of disputes were the stated reason for the August continuance. Neither the number of opt-outs, the number of revocation requests, nor the number of claims filed with the administrator has been made public.

If Boyer grants final approval, an appeal by the objectors is close to certain, and a Missouri appellate court would then be asked to test the futures subclass against Amchem and Ortiz on a record that is now complete.

When will Judge Boyer rule on Roundup settlement final approval?

There is no deadline and the court has not set one. The parties were to lodge proposed orders at the end of the week of the hearing, which is the ordinary signal that a written decision is being prepared rather than an oral ruling; Boyer said he could not predict how long it would take, and coverage of the hearing suggested a decision in the weeks that follow rather than the days. A settlement of this size, resting on a contested class-certification theory and facing a well-funded objector bloc, is an order that will be written to be defended on appeal, which argues for the longer end of any estimate.

Date	Event
17 February 2026	Monsanto announces the class settlement; King v. Monsanto Co. filed in the 22nd Judicial Circuit, City of St. Louis
4 March 2026	Judge Timothy Boyer grants preliminary approval and directs notice
May 2026	Objectors file constitutional challenge to the futures subclass, invoking Amchem and Ortiz
4 June 2026	Opt-out and objection deadline closes
25 June 2026	Supreme Court decides Monsanto Co. v. Durnell, 7-2, holding FIFRA preempts state failure-to-warn claims
9 July 2026	Original fairness hearing date, continued
6 August 2026	Court grants joint motion; hearing moved from 19 August to 14 September to process opt-out revocations and validity disputes
14 September 2026	Final approval hearing held; decision reserved; proposed orders directed
18 September 2026	No ruling on the docket

What happens to Roundup lawsuits if Judge Boyer rejects the settlement?

Refusing Roundup settlement final approval would not restore the status quo ante, because Durnell intervened in the meantime. Three consequences follow, and no competitor coverage has modeled them.

First, the roughly 65,000 pending claims revert to individual litigation in a doctrinal posture far weaker than the one in which they were filed. With failure-to-warn preempted, surviving theories narrow toward Design Defect, negligent testing, and theories that do not depend on what the label said — claims that are viable but historically less productive of the very large verdicts that drove Bayer to the table.

Second, the federal MDL is no longer the center of gravity it was. Only a few thousand actions remained pending before Judge Vince Chhabria in the Northern District of California by August 2026, with the bulk of the inventory in state courts. A rejected class settlement therefore disperses rather than consolidates, which is the outcome least attractive to a defendant seeking finality and least efficient for claimants' counsel carrying large inventories.

Third, the futures problem does not go away; it simply returns to the defendant's balance sheet as an open-ended provision. Bayer's earlier program, announced in 2020 at $10.9 billion, resolved on the order of 100,000 claims but conspicuously failed to close the tail, which is the institutional reason the company reached for a class device this time. Rejection would send it back to that problem with the additional knowledge that one state court has already declined the structure.

What it means for mass tort counsel, defendants, and clause drafters

For claimants' counsel with Roundup inventories. The operative variable is no longer the matrix but the calendar. Clients who stayed in are waiting on an order with no date attached; clients who opted out are holding claims that Durnell narrowed and are dependent on whether revocation requests are honored. Firms carrying substantial inventories face a working-capital question of exactly the kind that drives demand for Third-Party Litigation Funding, at a moment when funders' disclosure obligations are themselves under active federal rulemaking scrutiny.

For corporate defendants. Roundup settlement final approval in King is the live test of whether a state-court settlement class can deliver what the bankruptcy route — the Texas Two-Step and the Section 524(g) Trust — has struggled to deliver for non-asbestos mass torts: a binding resolution of claims that have not accrued. If Boyer approves and the approval survives appeal, the playbook for future mass tort resolution changes materially. If he refuses, or if an appellate court unwinds it on Amchem grounds, the futures problem stays where it has been for thirty years.

For drafters and the mass arbitration bar. The structural question Boyer is being asked — can one proceeding bind a population that has not yet been injured, on terms negotiated by counsel who represent both the injured and the not-yet-injured — is the same aggregation problem that Mass Arbitration poses from the opposite direction. A Class Action Waiver paired with an Arbitration Clause pushes claimants toward individualized proceedings that then reaggregate through Batching; a futures class pulls them into a single proceeding before they even have claims. Both are attempts to price an unknown population in advance, and both stand or fall on the adequacy of the representation and the quality of the notice. Practitioners tracking the AAA and JAMS mass arbitration rulebooks will recognize the fight over whether the $675 million fee was earned on behalf of people who cannot yet be identified; it is the fee-allocation problem of aggregate proceedings in a different costume.

For insurers and health plans. The dozen health care plans among the objectors are not sentimental participants. Their interest is in Medical Lien recovery and subrogation against a matrix that pays in tiers over two decades, and a settlement that fixes low ceilings for residential exposure limits what a plan can recover from a member's award. Their objection is a reminder that in aggregate resolutions the claimant is rarely the only party with a claim on the payment.

Frequently asked questions

Has the Roundup settlement been approved?

Not yet. Judge Timothy Boyer heard final argument on 14 September 2026 and reserved decision; preliminary approval was granted on 4 March 2026, but no final approval order had issued as of 18 September 2026.

How much does the Roundup settlement pay?

Individual awards run from roughly $10,000 to $165,000 across nine tiers, with occupational exposure at the top of the range and residential exposure capped substantially lower. A quick-pay option of roughly $6,000 to $14,500 is available to claimants who filed suit or a tolling agreement before 13 February 2026.

Who is in the Roundup class?

Two subclasses: people already diagnosed with non-Hodgkin lymphoma as of the settlement date, and people exposed to Roundup in the United States before 17 February 2026 who have not been diagnosed. The second group can claim only on diagnosis, within sixteen years of final approval.

Can I still opt out of the Roundup settlement?

No. The opt-out and objection deadline was 4 June 2026. The live disputes concern whether earlier opt-outs can be revoked after Monsanto Co. v. Durnell and whether particular opt-outs were valid.

How much are the lawyers asking for?

Class counsel seek $675 million, approximately 9.3 percent of the $7.25 billion maximum, payable from inside the fund rather than on top of it.

What did Monsanto v. Durnell decide?

On 25 June 2026 the Supreme Court held 7-2 that FIFRA preempts state-law failure-to-warn claims that would require a cancer warning in addition to, or different from, the EPA-approved label. The decision reversed a $1.25 million Missouri verdict and removed the theory that carried most Roundup claims.

When will the judge decide?

No date has been set. Proposed orders were due at the end of the week of the hearing, and a written decision is expected in the weeks that follow rather than the days.